Safety Alert: Falsified Mounjaro Identified
The MHRA has identified a falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection supplied through an online pharmacy in the UK. This alert applies to a specific batch and requires immediate awareness among clinical teams and patients.
Key Points
- Falsified product identified with batch number D873576
- Distribution traced to one online pharmacy supplier in the UK
- Mounjaro is a GLP-1 receptor agonist used in the management of type 2 diabetes
- Falsified medicines pose risks including inefficacy, contamination, and adverse effects
Affected Medication
- Mounjaro KwikPen 15mg pre-filled pens (batch D873576)
Recommended Actions
- Check any Mounjaro KwikPen 15mg stock, particularly batch D873576
- Do not supply or administer pens from the identified batch
- Advise patients who may have received this product to contact their healthcare provider immediately
- Report any suspected falsified medicines to the MHRA via the Yellow Card scheme
- Source all medicines through licensed, regulated suppliers only
Further Information
For the full MHRA drug safety update, visit the official MHRA alert page.